Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.65 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.65 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | ALB | P02768 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | RARB | P10826 | 1/20 | 0.65 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480706 | 1.00 | PTGS1 (0.65) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| SCHEMBL4478220 | 0.88 | CXCR1 (0.58) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| SCHEMBL5960821 | 0.88 | CXCR1 (0.58) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| SCHEMBL4476404 | 0.88 | CXCR1 (0.58) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| SCHEMBL5431716 | 0.86 | TSHR (0.52) | PTGS2CYP2C9TSHRMAPT | |
| SCHEMBL13074658 | 0.86 | TSHR (0.52) | PTGS2CYP2C9TSHRMAPT | |
| SCHEMBL4470338 | 0.84 | PTGS2 (0.61) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| SCHEMBL4482521 | 0.84 | PTGS2 (0.61) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| SCHEMBL4486987 | 0.80 | CXCR1 (0.59) | PTGS1PTGS2CXCR1CXCR2LMNA | |
| SCHEMBL4486986 | 0.80 | CXCR1 (0.59) | PTGS1PTGS2CXCR1CXCR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328057-B2 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | claimed |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | DOMPE PHA.R.MA S.P.A. (IT) | 2009-08-13 | — | — | US | claimed |
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | claimed |
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE PHA.R.MA S.P.A. (IT) | 2006-11-02 | — | — | US | claimed |
| US-9328057-B2 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | DOMPE PHA.R.MA S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | disclosed |
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE PHA.R.MA S.P.A. (IT) | 2006-11-02 | — | — | US | disclosed |
| EP-1581474-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | Dompé S.P.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004052830-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE S.P.A. (IT) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | NR1H4, MMP8, NR1I2 | PTGS1 664/4885PTGS2 803/4885CXCR1 392/4885 |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | NR1H4, MMP8, NR1I2 | PTGS1 664/4885PTGS2 803/4885CXCR1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.